http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113816953-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2021-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113816953-B |
| titleOfInvention | Toll-like receptor agonist resiquimod derivatives, and preparation and application thereof |
| abstract | The invention belongs to the technical field of medicines, and discloses Toll-like receptor agonist resiquimod derivatives, and preparation and application thereof. The Toll-like receptor agonist resiquimod derivative is one of the following structures. The method comprises the following steps: obtained by reacting resiquimod R848 with an acylchloride compound containing anhydride, acrylate or methacrylate. The Toll-like receptor agonist resiquimod derivative is used for preparing the Toll-like receptor 7/8 agonist and the anti-cancer drug, and the resiquimod derivative is used for preparing the anti-cancer drug in a bonding mode. The resiquimod derivative not only keeps the original medicinal activity, but also has high-activity reactive groups which are beneficial to the bonding of the resiquimod and easy delivery to tumor parts, improves the poor pharmacokinetics of the resiquimod and improves the bioavailability. |
| priorityDate | 2021-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.